Prevents organ rejection. ANDA 203859, held by Mylan Labs Ltd. Mycophenolate Mofetil Hydrochloride.
As of Nov 16, 2026, ANDA 203859 (Mycophenolate Mofetil Hydrochloride), held by Mylan Labs Ltd, was first approved by FDA on Mar 31, 2017, with 8 approved supplements and 0 published complete response letters.
Mycophenolate mofetil (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycophenolate Mofetil Hydrochloride500MG/VIAL · injectable;injection | Mycophenolate Mofetil Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 17REMS | Approved | None posted |
| Aug 13, 2024 | Supplement 15REMS | Approved | None posted |
| Mar 8, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 11, 2021 | Supplement 9REMS | Approved | None posted |
| Apr 21, 2021 | Supplement 7REMS | Approved | None posted |
| Jan 15, 2021 | Supplement 3REMS | Approved | None posted |
| Mar 31, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters